Kadowaki S - Search Results

1

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.

Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Mishima S, et al. Among authors: kadowaki s. Int J Clin Oncol. 2023 Oct;28(10):1237-1258. doi: 10.1007/s10147-023-02397-9. Epub 2023 Aug 20. Int J Clin Oncol. 2023. PMID: 37599324 Free PMC article.

2

Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.

Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Bando H, et al. Among authors: kadowaki s. Jpn J Clin Oncol. 2012 Dec;42(12):1146-51. doi: 10.1093/jjco/hys160. Epub 2012 Oct 15. Jpn J Clin Oncol. 2012. PMID: 23071293

3

Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.

Kadowaki S, Yatabe Y, Hirakawa H, Komori A, Kondoh C, Hasegawa Y, Muro K. Kadowaki S, et al. Case Rep Oncol. 2013 Sep 10;6(3):450-5. doi: 10.1159/000355219. eCollection 2013. Case Rep Oncol. 2013. PMID: 24163659 Free PMC article.

4

Durable response of human epidermal growth factor receptor-2-positive gastric adenosquamous carcinoma to trastuzumab-based chemotherapy.

Kadowaki S, Yatabe Y, Nitta S, Ito Y, Muro K. Kadowaki S, et al. Case Rep Oncol. 2014 Mar 19;7(1):210-6. doi: 10.1159/000362088. eCollection 2014 Jan. Case Rep Oncol. 2014. PMID: 24803897 Free PMC article.

5

Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site.

Hasegawa H, Ando M, Yatabe Y, Mitani S, Honda K, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K. Hasegawa H, et al. Among authors: kadowaki s. Clin Oncol (R Coll Radiol). 2018 Oct;30(10):667-673. doi: 10.1016/j.clon.2018.06.012. Epub 2018 Jul 6. Clin Oncol (R Coll Radiol). 2018. PMID: 30196846

6

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.

Naito Y, Mishima S, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Naito Y, et al. Among authors: kadowaki s. Int J Clin Oncol. 2023 Jul;28(7):827-840. doi: 10.1007/s10147-023-02345-7. Epub 2023 May 22. Int J Clin Oncol. 2023. PMID: 37212982 Free PMC article.

7

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.

Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Mishima S, et al. Among authors: kadowaki s. Int J Clin Oncol. 2023 Aug;28(8):941-955. doi: 10.1007/s10147-023-02360-8. Epub 2023 Jun 10. Int J Clin Oncol. 2023. PMID: 37300720 Free PMC article.

8

Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab.

Wakatsuki T, Ishizuka N, Hironaka S, Minashi K, Kadowaki S, Goto M, Shoji H, Hirano H, Nakayama I, Osumi H, Ogura M, Chin K, Yamaguchi K, Takahari D. Wakatsuki T, et al. Among authors: kadowaki s. Int J Clin Oncol. 2024 Apr 8. doi: 10.1007/s10147-024-02509-z. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38589679

9

Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.

Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A. Kiyota N, et al. Among authors: kadowaki s. Jpn J Clin Oncol. 2009 Apr;39(4):225-30. doi: 10.1093/jjco/hyp002. Epub 2009 Feb 10. Jpn J Clin Oncol. 2009. PMID: 19211574

10

[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].

Yoda Y, Yoshino T, Kadowaki S, Bando H, Okano S, Fukushima H, Fuse N, Tahara M, Doi T, Ohtsu A. Yoda Y, et al. Among authors: kadowaki s. Gan To Kagaku Ryoho. 2009 Jun;36(6):1003-6. Gan To Kagaku Ryoho. 2009. PMID: 19542725 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

434 results

Search Page